Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L D Lewis

Showing results (101-110 of 105) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 105 results.
International Journal of Radiation Oncology, Biology, Physics|August 3, 2001
Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreasJ M Pipas, S E Mitchell, R J Barth, et al.
Journal of Immunological Methods|February 27, 2001
Bispecific antibody-targeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in vivoP K Wallace, P A Kaufman, L D Lewis, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 24, 2001
Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI X anti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neuT Schwaab, L D Lewis, B F Cole, et al.
Clinical Pharmacology and Therapeutics|October 1, 2010
An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumorsB C Goh, N J Reddy, U B Dandamudi, et al.
International Journal of Clinical Pharmacology and Therapeutics|March 14, 2009
Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumorsR L Oostendorp, J Loftiss, S Goel, et al.
Pageof 11

Showing results (101-110 of 105) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 105 results.
International Journal of Radiation Oncology, Biology, Physics|August 3, 2001
Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreasJ M Pipas, S E Mitchell, R J Barth, et al.
Journal of Immunological Methods|February 27, 2001
Bispecific antibody-targeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in vivoP K Wallace, P A Kaufman, L D Lewis, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 24, 2001
Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI X anti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neuT Schwaab, L D Lewis, B F Cole, et al.
Clinical Pharmacology and Therapeutics|October 1, 2010
An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumorsB C Goh, N J Reddy, U B Dandamudi, et al.
International Journal of Clinical Pharmacology and Therapeutics|March 14, 2009
Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumorsR L Oostendorp, J Loftiss, S Goel, et al.
Pageof 11